



RECEIVED
MAY 16 2003
TECH CENTER 1600/2900

	CDR1				CDR2			
	10	20	30	40	50	60		
CGS1	QVQLVESGGGLVQPGGSLRLSCAVSGFTFS SYAMS WVRQAPGKGLEWVS AISGSGGSTYYADSVKGG							
CGS2	EVQLVESGGGLVQPGGSLRLSCAAASGFTFS SYAMS WVRQAPGKGLEWVS AISGSGGSTYYADSVKGG							


FIG. 1A



RECEIVED
MAY 16 2003
TECH CENTER 1600/2900

		CDR1				CDR2	
		10	20	30	40	50	
CGS1		SSELTQDPAVSV	ALGQTVRITC	QGD	SLRSYYAS	WYQQKPGQAPVLVIY	GKNNRPS
CGS2		SSELTQDPAVSV	ALGQTVRITC	QGD	SLRSYYAS	WYQQKPGQAPVLVIY	GKNNRPS
		CDR3					
		60	70	80	90	100	
CGS1		GIPDRFSGSSSG	NTASLTTTGAQAE	DEADYYC	NSSPVVLNGV	FGG	IKLTVLG
CGS2		GIPDRFSGSSSG	NTASLTTTGAQAE	DEADYYC	NSSPFFHNLV	FGG	IKLTVLG

FIG. 1B






FIG. 2B



	CGS-1	CGS-2	BC-1	IST-6
1	-	-	-	+
2	+	+	+	-
3	-	-	-	+
4	+	+	+	-
5	-	+	-	-
6	-	+	-	-

rec FN 2-11 (B-)

rec FN 2-11 (B+)

rec FN 7-9 (B-)

rec FN 7-9 (B+)

fusion protein λ ED-B

fusion protein λ chFN 60

2

3

4

5

6

7

8

9

10

11

2

3

4

5

6

7

8

9

10

11

7

8

9

7

8

9

B

7

B

FIG. 3A




FIG. 3B




FIG. 4

24 h

48 h

scFv(28SI)

t

t

b

scFv(CGS-2) [large necrotic tumour]

t

t

b

scFv(CGS-2) [small tumour]

t


t

b

RECEIVED
MAY 13 2003
1129 U.S. PTO



05/13/03
1129 U.S. PTO



t = tumour

b = bladder